(Q37401338)

20 August 2017

1 reference

title

Molecular outcome prediction in mantle cell lymphoma (English)

1 reference

20 August 2017

3

Andreas Rosenwald

1 reference

20 August 2017

Elena M Hartmann

1

1 reference

20 August 2017

German Ott

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

63-73

1 reference

Advances in the understanding of mantle cell lymphoma

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Current treatment approaches for mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Mantle cell lymphoma: evolving novel options

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Repp86: a new prognostic marker in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

CDK4andMDM2Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-typeINK4a/ARFLocus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.63

21 January 2018

Identifiers

DOI

10.2217/14796694.5.1.63

1 reference

20 August 2017

1 reference